Press Releases

Fulcrum Therapeutics, Inc.® a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference in Miami, FL on March 11, 2025 at 8:40 am ET. The webcast of the fireside chat will be accessible HERE and by visiting the "Events and Presentations" section of Fulcrum T

Arvinas, Inc. a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three upcoming investor conferences: Leerink Partners Global Healthcare Conference 2025 on Tuesday, March 11. Andrew Saik, Chief Financial Officer, and Randy Teel, Ph.D., Chief Business Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events

Eledon Pharmaceuticals, Inc. today announced that Steve Perrin, Ph.D., Chief Scientific Officer and President, will participate in a fireside chat at the upcoming Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 2:20 p.m. ET (11:20 a.m. PT). To register in advance for the fireside chat webcast, sign up here. A webcast replay will be accessible following the live session on the Company’s website under Events. About Eledon Pharmaceut

Compugen Ltd. a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference, Miami Beach, Florida, on Tuesday, March 11, 2025 at 8:00 AM ET. A live webcast of the presentation will be available on the events page of the Investor Relations section of Compugen's website at www.cgen.com. A replay will be available following the li

Dermata Therapeutics, Inc. a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced that the last patient has completed their last visit in the Company's first pivotal Phase 3 Spongilla Treatment for Acne Research (STAR-1) trial of XYNGARI™, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. The Company remains on track to announce topline data by the end of March 20

METiS Pharmaceuticals, a clinical-stage, AI-driven biotechnology company specializing in innovative drug delivery technologies, today announced the appointment of Mark Herbert as Chief Business Officer (CBO). In this role, Mr. Herbert will lead global business development, build key partnerships, and explore new opportunities to support METiS' growth and advance the commercialization of its drug delivery technologies. With over 20 years of experience in the biotechnology and pha

Protega Pharmaceuticals Inc., the innovative specialty pharmaceutical company that launched ROXYBOND™ (oxycodone hydrochloride), the first and only FDA-approved abuse-deterrent immediate-release (IR) pain medication in the U.S., announced today that it is collaborating with Wellgistics Health NASDAQ (WGRX) to support pharmacist education on abuse-deterrent pain management options and regulatory compliance as well as increase patient access to the drug for appropriately prescribed patien

Avobis Bio LLC, a clinical stage company developing implantable cell therapies, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for AVB-114, the Company's lead therapeutic candidate for Crohn's perianal fistulas. FDA Fast Track designation is intended to facilitate the development and expedite the review of medicines that demonstrate the potential to treat serious conditions and fill an unmet medical need. Compelling result

CARsgen Therapeutics Holdings Limited, a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to satricabtagene autoleucel ("satri-cel", CT041) for the treatment of Claudin18.2-positive advanced gastric/gastroesophageal junction cancer (G/GEJ) in patients who

Avirmax Biopharma, Inc., a leader in developing the next generation of AAV gene therapies, today announced the commencement of Investigational New Drug (IND)-enabling studies of ABI-201, a potential first-in-class AAV vector that delivers three genes to correct the dysregulation of complement activation, anti-inflammation, to protect retinal pigment epithelia and photoreceptors as well as to block retinal neovascularization. ABI-201 is constructed to achieve durable expression of these transg